135 related articles for article (PubMed ID: 37788412)
1. Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial.
Garon EB; Lu S; Goto Y; De Marchi P; Paz-Ares L; Spigel DR; Thomas M; Yang JC; Ardizzoni A; Barlesi F; Orlov S; Yoshioka H; Mountzios G; Khanna S; Bossen C; Carbini M; Turri S; Myers A; Cho BC
J Clin Oncol; 2024 Jan; 42(2):180-191. PubMed ID: 37788412
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.
Herbst RS; Wu YL; John T; Grohe C; Majem M; Wang J; Kato T; Goldman JW; Laktionov K; Kim SW; Yu CJ; Vu HV; Lu S; Lee KY; Mukhametshina G; Akewanlop C; de Marinis F; Bonanno L; Domine M; Shepherd FA; Urban D; Huang X; Bolanos A; Stachowiak M; Tsuboi M
J Clin Oncol; 2023 Apr; 41(10):1830-1840. PubMed ID: 36720083
[TBL] [Abstract][Full Text] [Related]
3. Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial.
Paz-Ares L; Goto Y; Wan-Teck Lim D; Halmos B; Chul Cho B; Cobo M; Luis González Larriba J; Zhou C; Demedts I; Atmaca A; Baka S; Mookerjee B; Portella S; Zhu Z; Wu J; Demanse D; Dharan B; Reck M
Lung Cancer; 2024 Mar; 189():107451. PubMed ID: 38354535
[TBL] [Abstract][Full Text] [Related]
4. Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial.
Tan DSW; Felip E; de Castro G; Solomon BJ; Greystoke A; Cho BC; Cobo M; Kim TM; Ganguly S; Carcereny E; Paz-Ares L; Bennouna J; Garassino MC; Schenker M; Kim SW; Brase JC; Bury-Maynard D; Passos VQ; Deudon S; Dharan B; Song Y; Caparica R; Johnson BE
J Clin Oncol; 2024 Jan; 42(2):192-204. PubMed ID: 38039427
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
Vansteenkiste JF; Cho BC; Vanakesa T; De Pas T; Zielinski M; Kim MS; Jassem J; Yoshimura M; Dahabreh J; Nakayama H; Havel L; Kondo H; Mitsudomi T; Zarogoulidis K; Gladkov OA; Udud K; Tada H; Hoffman H; Bugge A; Taylor P; Gonzalez EE; Liao ML; He J; Pujol JL; Louahed J; Debois M; Brichard V; Debruyne C; Therasse P; Altorki N
Lancet Oncol; 2016 Jun; 17(6):822-835. PubMed ID: 27132212
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.
Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Wei YC; Liu YY; Chen C; Cheng Y; Yin R; Yang F; Ren SX; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yang JJ; Yan HH; Yang XN; Liu SY; Zhou Q; Wu YL
J Clin Oncol; 2021 Mar; 39(7):713-722. PubMed ID: 33332190
[TBL] [Abstract][Full Text] [Related]
7. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Shen Y; Liu YY; Chen C; Cheng Y; Xu L; Wang J; Fei K; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yan HH; Yang XN; Zhou Q; Wu YL;
Lancet Oncol; 2018 Jan; 19(1):139-148. PubMed ID: 29174310
[TBL] [Abstract][Full Text] [Related]
8. Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial.
Hui Z; Men Y; Hu C; Kang J; Sun X; Bi N; Zhou Z; Liang J; Lv J; Feng Q; Xiao Z; Chen D; Wang Y; Li J; Wang J; Gao S; Wang L; He J
JAMA Oncol; 2021 Aug; 7(8):1178-1185. PubMed ID: 34165501
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.
O'Brien M; Paz-Ares L; Marreaud S; Dafni U; Oselin K; Havel L; Esteban E; Isla D; Martinez-Marti A; Faehling M; Tsuboi M; Lee JS; Nakagawa K; Yang J; Samkari A; Keller SM; Mauer M; Jha N; Stahel R; Besse B; Peters S;
Lancet Oncol; 2022 Oct; 23(10):1274-1286. PubMed ID: 36108662
[TBL] [Abstract][Full Text] [Related]
10. Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design.
Garrido P; Pujol JL; Kim ES; Lee JM; Tsuboi M; Gómez-Rueda A; Benito A; Moreno N; Gorospe L; Dong T; Blin C; Rodrik-Outmezguine V; Passos VQ; Mok TS
Future Oncol; 2021 Apr; 17(12):1459-1472. PubMed ID: 33648347
[TBL] [Abstract][Full Text] [Related]
11. Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial.
Felip E; Altorki N; Zhou C; Vallières E; Martínez-Martí A; Rittmeyer A; Chella A; Reck M; Goloborodko O; Huang M; Belleli R; McNally V; Srivastava MK; Bennett E; Gitlitz BJ; Wakelee HA
Ann Oncol; 2023 Oct; 34(10):907-919. PubMed ID: 37467930
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.
Kelly K; Altorki NK; Eberhardt WE; O'Brien ME; Spigel DR; Crinò L; Tsai CM; Kim JH; Cho EK; Hoffman PC; Orlov SV; Serwatowski P; Wang J; Foley MA; Horan JD; Shepherd FA
J Clin Oncol; 2015 Dec; 33(34):4007-14. PubMed ID: 26324372
[TBL] [Abstract][Full Text] [Related]
13. A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer.
Okamoto T; Yano T; Shimokawa M; Takeo S; Yamazaki K; Sugio K; Takenoyama M; Nagashima A; Tsukamoto S; Hamatake M; Yokoyama H; Ueda H; Motohiro A; Tagawa T; Shoji F; Kometani T; Saito G; Fukuyama Y; Toyokawa G; Osoegawa A; Emi Y; Maehara Y;
Lung Cancer; 2018 Oct; 124():255-259. PubMed ID: 30268470
[TBL] [Abstract][Full Text] [Related]
14. International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer.
Novello S; Torri V; Grohe C; Kurz S; Serke M; Wehler T; Meyer A; Ladage D; Geissler M; Colantonio I; Cauchi C; Stoelben E; Ceribelli A; Kropf-Sanchen C; Valmadre G; Borra G; Schena M; Morabito A; Santo A; Gregorc V; Chiari R; Reck M; Schmid-Bindert G; Folprecht G; Griesinger F; Follador A; Pedrazzoli P; Bearz A; Caffo O; Dickgreber NJ; Irtelli L; Wiest G; Monica V; Porcu L; Manegold C; Scagliotti GV
Ann Oncol; 2022 Jan; 33(1):57-66. PubMed ID: 34624497
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.
Zhao P; Zhen H; Zhao H; Zhao L; Cao B
BMC Cancer; 2022 Mar; 22(1):328. PubMed ID: 35346117
[TBL] [Abstract][Full Text] [Related]
16. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.
Goss GD; O'Callaghan C; Lorimer I; Tsao MS; Masters GA; Jett J; Edelman MJ; Lilenbaum R; Choy H; Khuri F; Pisters K; Gandara D; Kernstine K; Butts C; Noble J; Hensing TA; Rowland K; Schiller J; Ding K; Shepherd FA
J Clin Oncol; 2013 Sep; 31(27):3320-6. PubMed ID: 23980091
[TBL] [Abstract][Full Text] [Related]
17. Safety of adjuvant atezolizumab after pneumonectomy/bilobectomy in stage II-IIIA non-small cell lung cancer in the randomized phase III IMpower010 trial.
Lee JM; Vallières E; Ding B; Johnson A; Bhagwakar J; Rashidi S; Zhu QC; Gitlitz BJ; Weksler B; Costas K; Altorki N
J Thorac Cardiovasc Surg; 2023 Sep; 166(3):655-666.e7. PubMed ID: 36841745
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Felip E; Altorki N; Zhou C; Csőszi T; Vynnychenko I; Goloborodko O; Luft A; Akopov A; Martinez-Marti A; Kenmotsu H; Chen YM; Chella A; Sugawara S; Voong D; Wu F; Yi J; Deng Y; McCleland M; Bennett E; Gitlitz B; Wakelee H;
Lancet; 2021 Oct; 398(10308):1344-1357. PubMed ID: 34555333
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.
Wakelee HA; Dahlberg SE; Keller SM; Tester WJ; Gandara DR; Graziano SL; Adjei AA; Leighl NB; Aisner SC; Rothman JM; Patel JD; Sborov MD; McDermott SR; Perez-Soler R; Traynor AM; Butts C; Evans T; Shafqat A; Chapman AE; Kasbari SS; Horn L; Ramalingam SS; Schiller JH;
Lancet Oncol; 2017 Dec; 18(12):1610-1623. PubMed ID: 29129443
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase II trial of cisplatin plus gemcitabine versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT0703).
Fukumoto SI; Oizumi S; Harada M; Sukoh N; Nakano K; Fuke S; Sakakibara-Konishi J; Takamura K; Ito K; Fujita Y; Nishigaki Y; Harada T; Akie K; Kinoshita I; Amano T; Isobe H; Dosaka-Akita H; Nishimura M;
Cancer Chemother Pharmacol; 2020 Jul; 86(1):117-127. PubMed ID: 32564128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
